Copper-64 Radiopharmaceuticals for Theranostic Applications

Closed for proposals

Project Type

Coordinated Research Project

Project Code

F22067

CRP

2106

Approved Date

9 December 2015

Status

4 - Closed

Start Date

18 March 2016

Expected End Date

17 March 2020

Completed Date

2 July 2020

Participating Countries

Australia
Brazil
Canada
China
Denmark
India
Iran (Islamic Republic of)
Mexico
Netherlands
Pakistan
Saudi Arabia
Syrian Arab Republic
United States of America

Description

This Coordinated Research Project (CRP) will identify important technical issues related to the production and quality control of new theranostic copper-64 radiopharmaceuticals.  Cu-64 is the only known radionuclide in the nuclear medicine transmuting through three different routes namely positron decay, beta decay and electron capture. Consequently these result in emission of positron particles which can be used in positron emission tomography (PET) and beta particles and Auger electrons both of which find use in therapy. Thus, this unique nature allows Cu-64 to be used for both diagnostic and therapeutic purpose in nuclear medicine and has earned it the name 'theranostic' radionuclide. Recent studies showed that Cu-64 in the most simple form (64Cu-CuCl2) as well as linked to a variety of bioactive molecules can be used as theranostic agents in human malignancies such as prostate, glioblastoma, melanoma, breast cancers) and also diagnosis of human copper-associated diseases such as atherosclerosis, Alzheimer’s etc.This CRP is focused on the application of newly-discovered theranostic properties of copper-64 cation as well as developing and evaluation of most promising Cu-64 chelated targeting theranostic agents for therapy and diagnosis of human diseases.

Objectives

Based on the interesting preliminary data on the application of 64CuCl2 radiopharmaceutical in human cancers for diagnosis and therapy, the working group is focused on thorough preclinical/clinical investigations of the radiopharmaceutical. For these investigations, the priority is to better understand, and exploit for diagnostic and therapeutic purposes and endogenous Cu transport mechanisms. Cancer models to be investigated include prostate cancer, glioblastoma, lymphoma, breast cancer and melanoma. The unique opportunity of 64Cu to target various human cancers such as prostate, glioblastoma and melanoma also offers the opportunity to study the in-vitro and in-vivo behaviour of 64CuCl2 in these disease models. We therefore proposed to also evaluate the Cu-trafficking mechanisms, microdosimetry, radiobiology, etc. in comparison to other existing therapeutic radiopharmaceuticals (where available). A high incidence of receptor expression in either early- or late-stage/metastatic cancers creates potential for development of new and innovative monovalent and bivalent 64Cu radioligands to tailor receptor-specific uptake, optimize localization in cancerous tissues, and minimize uptake in normal tissues to produce high-quality, high-contrast PET images for early diagnosis and staging of human cancers and atherosclerotic plaques. In addition, these agents offer the added opportunity to be used for targeted therapy due to ideal particle emissions for the three decay modes. In these research investigations, we propose usage of selected targeting vectors (mono- or bivalent) to be delivered to participating countries to perform in-vitro and in-vivo evaluation of agents. For example, based upon a thorough review of the literature, the focal points of this CRP are to be peptides (e.g. particularly GRPR targeting, integrin targeting, somatostatin receptor targeting, etc.) and small molecules (e.g. PSMA inhibitors), and antibodies. In view of previous research investigations from numerous research groups around the world, the participants proposed usage of NOTA- or sarcophagine-based complexing agents for further evaluations to conjugate the targeting vectors in order to complex and stabilize the 64Cu metal centre.

Specific objectives

64Cu Radiolabelling, in-vitro, and in-vivo Investigations Using Antibody-Based Targeting Vectors.

64Cu Radiolabelling, in-vitro, and in-vivo Investigations Using Bivalent aVb3/GRPR-Targeting Peptides.

64Cu Radiolabelling, in-vitro, and in-vivo Investigations Using PSMA-Targeting Small Molecule.

64Cu Radiolabelling, in-vitro, and in-vivo Investigations Using SSTR-2-Targeting Peptides.

Investigations of 64Cu Agents in Labelling of Mononuclear Leukocytes and Stem Cells.

Preclinical, Dosimetry, and Clinical Investigations Using 64CuCl2 for Theranostic Applications.

Usage of DOTHA2 for Conjugation to Varying Biomolecules.

Impact

The outcome of investigations of this CRP has addressed important technical issues associated with the usage of 64CuCl2.
The current CRP also indicated new and emerging technologies for the production of 64CuCl2 using cyclotrons and reactors.
This CRP reported the development of new small molecules and peptide/antibody-based 64Cu-tracers for diagnostic imaging and therapy. These new theranostic agents would be useful in the management of various types of cancers.
The output from this CRP is a technological asset to the IAEA Member States.
The technology transfer from this CRP will benefit the young and upcoming research groups around the globe.
Through this CRP many graduate students contributed to the development of 64Cu-radiopharmaceuticals and they will be a driving force for future production of radioisotopes and radiopharmaceutical activities in the Member States.
Participants of the CRP discussed the different aspects of Cu-64 radiopharmaceuticals during the RCMs that led to the preparation of an IAEA publication already submitted to IAEA publication section.

Relevance

This Coordinated Research Project (CRP) identified important technical issues associated with the usage of 64CuCl2 as a theranostic agent for administration to human patients presenting with a host of cancer disease. These cancers include but are not limited to prostate, breast, neuroendocrine, uterine, and glioblastoma multiform. In addition, Member States have described interests in radiolabelling investigations of prostate specific membrane antigen (PSMA) and other small molecules. The emerging technological advances for diagnosis of PSMA-expressing prostate cancer in clinical studies provide an important point of focus for participating Member States in the CRP. This CRP focuses primarily upon research strategies developed between the Member States to produce new 64Cu-tracers having potential as theranostic radiopharmaceuticals.

CRP Publications

Type

Journal

Year

2019

Description

Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, Akhurst TA, Drummond E, Roselt P, Callahan J, Price R, Jeffery CM, Hong E, Noonan W, Herschtal A, Hicks LJ, Hedt A, Harris M, Paterson BM, Donnelly PS. 64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. J Nucl Med. 2019 Jun;60(6):777-785.

Country/Organization

Australia

Type

IAEA Book Series, PC approved

Year

2020

Description

Copper-64 Radiopharmaceuticals; Production, Quality Control and Clinical Applications

Country/Organization

IAEA

Type

Conference

Year

2019

Description

Kjaer, A. Cu-64-DOTATATE somatostatin receptor Imaging in neuroendocrine tumors: experience from 500 patients at Copenhagen ENETS Center of Excellence. Journal of Nuclear Medicine 2019, 60, 504.

Country/Organization

Denmark

Type

Conference

Year

2016

Description

S. Ait-Mohand, V. Dumulon-Perreault, F. Benard B. Guérin. Design optimization of a new 64Cu/NOTA truncated NPY analog with improved stability and Y1 affinity, the first step toward successful breast cancer PET Imaging. J Nucl Med, 2016, 57:1076.

Country/Organization

Canada

Type

conference

Year

2019

Description

Preparation and biological assessment of 64Cu-NOTA-anti EGFR as a Radioimmunoconjugate for Diagnosis of EGFR+ ESCC by PET

Country/Organization

Iran

Type

Thesis

Year

2019

Description

Edgar A. Aguilar-Ortiz (PostDoc), Synthesis, characterization and evaluation of macrocyclic porphyrine systems, as potential chelate agents for 64Cu-radiopharmaceuticals.

Country/Organization

MEXICO

Type

Journal

Year

2018

Description

Børresen, B.; Henriksen, J.R.; Clergeaud, G.; Jørgensen, J.S.; Melander, F.; Elema, D.R.; Szebeni, J.; Engelholm, S.A.; Kristensen, A.T.; Kjær, A.; et al. Theranostic Imaging May Vaccinate against the Therapeutic Benefit of Long Circulating PEGylated Liposomes and Change Cargo Pharmacokinetics. ACS Nano 2018, 12, 11386–11398

Country/Organization

Denmark

Type

Conference

Year

2017

Description

C. Zhang, J. Pan, K.-S. Lin, I. Dude, J. Lau, H. Merkens, S. Jenni, B. Guérin, and F. Benard. Improved 68Ga-labelled truncated peptides targeting the neuropeptide Y1 receptor for cancer imaging by positron emission tomography. J Nucl Med 2016 57:1160.

Country/Organization

Canada

Type

Thesis

Year

2018

Description

M. van Bezoen,, internship in the Baccalaureate degree entitled:”Synthesis and validation of cold refrence compounds Cu-, Ga- and AlF-ACUPA-benzyl-TU-NOTA

Country/Organization

NETHERLANDS

Type

Journal

Year

2019

Description

Anjum, Rukhsana; Palanimuthu, Duraippandi; Kalinowski, Danuta; Lewis, William; Park, Kyung Chan; Kovacevic, Zaklina; Khan, Irfan Ullah; Richardson, Des; Synthesis, Characterization and In Vitro Anti-Cancer Activity of Copper and Zinc Bis (Thiosemicarbazone) Complexes; Inorg. Chem. 2019, 58 (20): 13709-13723. DOI: 10.1021/acs.inorgchem.9b01281

Country/Organization

Pakistan

Type

Abstracts from the Proceedings of a Meeting

Year

2016

Description

Z. Szucs 1*, B. Alirezapour. Simultaneous production of 55Co, 57Ni and 64Cu for PET imaging; 5th Workshop of the Decay Data Evaluation Project

Country/Organization

IRAN

Type

Journal

Year

2019

Description

E. Aguilar-Orti´z, A.R. Jalilian, M.A. Avila-Rodriguez, Synthesis, characterization and evaluation of a 64Cu-labeled macrocyclic-porphyrin as a potential chelator for Cu-based radiopharmaceuticals, J. Radioanal. Nucl. Chem. 320, 79-86 (2019).

Country/Organization

Mexico

Type

Thesis

Year

2019

Description

Benito Gongora Servin (Master), Preclinical evaluation and radiation dosimetry of 64Cu-DOTA-iPSMA.

Country/Organization

MEXICO

Type

Thesis

Year

2019

Description

N. Mansour, PhD student

Country/Organization

CANADA

Type

Journal

Year

2018

Description

Gutfilen B, Souza SAL, Valentini G. Copper-64: a real theranostic agent. Drug Des Devel Ther Oct 2,12: 3235-3245, 2018.

Country/Organization

Brazil

Type

Conference

Year

2019

Description

J. Carrasco-Hernandez, J. Ramos-Mendez, M.A. Avila-Rodri´guez, Determination of S-values and characterization of direct damage to DNA induced by Auger electrons from Copper-64, EJNMMI 46, S197 (2019).

Country/Organization

Mexico

Type

Conference

Year

2019

Description

Halldorsdottir, H. Flexible Copper-64-nanoparticle-based cell labeling system allows for in vivo tracking of adoptively transferred T-cells by PET/CT. JOURNAL FOR IMMUNOTHERAPY OF CANCER 2019, 7.

Country/Organization

Denmark

Type

Thesis

Year

2017

Description

R.S.B.H. Schreuder, master thesis entitled:’ Development of 64Cu-labeled radiopharmaceuticals for neuroendocrine tumor detection with positron emission tomography: A comparison between 64Cu-NODAGA-NOC, 68Ga-NODAGA-NOC and 68Ga-DOTA-TOC”

Country/Organization

NETHERLANDS

Type

Conference

Year

2016

Description

S. Ait-Mohand, V. Dumulon-Perreault, B. Guérin. A new NPY-Y1R targeting peptide for breast cancer PET imaging. ESRR’16 – 18th European Symposium on Radiopharmacy and Radiopharmaceuticals, April 07-10, 2016, Salzburg, Austria. EJNMMI Radiochem. Chem. 2016, S1 OP05.

Country/Organization

Canada

Type

PATENT

Year

2019

Description

Fedor Zhuravlev; Krisitna Pedersen Separation of Radiometals, P20367WO, filed on August 5th, 2019

Country/Organization

DENMARK

Type

conference

Year

2018

Description

B. Guérin, Outils pour l’imagerie TEP, une ouverture vers le développement de théranostiques. Lecture at UQAM's chemistry department, Montreal, Quebec, CA, November 15, 2018.

Country/Organization

Canada

Type

conference

Year

2019

Description

Preparation and biological assessment of 64Cu-NOTA-anti ROR1 as a Radioimmunoconjugate for Diagnosis of ROR1+ breast cancer by PET, 2nd International Symposium of Trends of Radiopharmaceuticals (IAEA), Location: Vienn, Austria, 2019

Country/Organization

Iran

Type

Journal

Year

2017

Description

M.A. Avila-Rodriguez, C. Rios, J. Carrasco-Hernandez, J.C. Manrique-Arias, R. Martinez-Hernandez, F.O. Garci´a-Pe´rez, A.R. Jalilian, E. Martinez-Rodriguez, M.E. Romero-Pin~a, A. Diaz-Ruiz, Biodistribution and Radiation Dosimetry of [64Cu]Copper Dichloride: First-in-Human Study in Healthy Volunteers, EJNMMI Res. 7, 98 (2017).

Country/Organization

Mexico

Type

Journal

Year

2020

Description

Andersen, T.L.; Baun, C.; Olsen, B.B.; Dam, J.H.; Thisgaard, H. Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE. Journal of Nuclear Medicine, 2020, 61, 228–233

Country/Organization

Denmark

Type

conference

Year

2019

Description

Gutfilen B; Valentini G. The role of 64CuCl2 as a theranostic agent in Alzhemeir’s Disease. International Conference on Alzheimer’s Disease & Dementia, Paris, França, 2019.

Country/Organization

Brazil

Type

Conference

Year

2019

Description

Pedersen, K.S.; Zhuravlev, F. Towards continuous cyclotron production of PET radiometals: Membrane-based liquid-liquid extraction in flow of gallium-68, copper-64, zirconium-89, and titanium-45. Journal of Labelled Compounds and Radiopharmaceuticals 2019, 62.

Country/Organization

Denmark

Type

conference

Year

2018

Description

Irfan Ullah Khan, Rizwana Zahoor, Nouroze Gul, Abubaker Shahid, Fozia Iram, Establishing Theranostics and Nano Theranostics in Pakistan

Country/Organization

Pakistan

Type

Peer-reviewed Journal Article

Year

2016

Description

J.C. Manrique-Arias, J. Carrasco-Herna´ndez, P.G. Reyes, M.A. Avila-Rodriguez, Biodistribution in rats and human dosimetry estimation of 64CuCl2, a potential theranostic tracer, Appl. Radiat. Isot. 115, 18-22

Country/Organization

MEXICO

Type

conference

Year

2020

Description

Hailong Zhao, Tianwei Luo, Xuhu Huang, Zequan Li, Mengyi Chen, Lin Xu, Ning Wang, Xuesong Deng, Jin Du, Hongyu Li. Preparation and preliminary biodistribution study of 64Cu-NODAGA-NOC. Abstract. 10th International conference on isotopes, 2020, Feb. 3-7.

Country/Organization

China

Type

conference

Year

2020

Description

2) Hailong Zhao, Tianwei Luo, Xuhu Huang, Zequan Li, Mengyi Chen, Ning Wang, Lin Xu, Hongyu Li. Preliminary biodistribution and PET imaging study of 64CuCl2 in model mice bearing melanoma. J. Isotopes.

Country/Organization

China

Type

Conference

Year

2017

Description

M. Paquette, V. Dumulon-Perreault, S. Ait-Mohand, B. Guérin. A New 64Cu-Labeled, Metabolic-Resistant Peptide with Nanomolar Affinity for NPY-Y1R for Breast Cancer Targeting. EANM’17, Vienna, Austria, October 21-25, 2017. EJNMMI 2017

Country/Organization

Canada

Type

Journal

Year

2020

Description

J. Carrasco-Herna´ndez, J. Ramos-Me´ndez, B. Faddegon, A.R. Jalilian, M. Moranchel, M.A. A´vila-Rodri´guez. Monte Carlo track-structure for the radionuclide Copper-64: Characterization of S-values, nanodosimetry and quantification of direct damage to DNA, Phys. Med. Biol. (2020).

Country/Organization

Mexico

Type

Ph.D Dissertation/Master’s Theses

Year

2017

Description

Jhonatan Carrasco-Hernandez (Doctorate’s degree), Evaluating the potential of [64Cu]CuCl2 as a theranostic agent.

Country/Organization

MEXICO

Type

conference

Year

2018

Description

B. Guérin, New 64Cu peptides for prostate and breast cancers for PET imaging, 2nd Research Coordination Meeting on Copper-64 Radiopharmaceuticals for Theranostic Applications 7-11 May 2018, IAEA Headquarters Vienna, Austria

Country/Organization

Canada

Type

conference

Year

2019

Description

Gutfilen B; Valentini G. Use of 64CuCl2 as a theranostic agent in gliblastoma tumor: A case report. 3rd International Cancer Conference & Expo, Baltimore, USA, 2019.

Country/Organization

Brazil

Type

Journal

Year

2018

Description

N. Mansour, M. Paquette, S. Ait-Mohand, V. Dumulon-Perreault, B. Guérin. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [64Cu]-DOTHA2-PEG-RM26. Nucl. Med. Biol. 2018, 56, 31–38.

Country/Organization

Canada

Type

Ph.D Dissertation/Master’s Theses

Year

2016

Description

Ms.c Thesis: Preparation and Quality Control of 64Cu-PCTA- Anti MUC1 as radioimmunoconjugate for PET Imaging. Fatemeh Karami . Started from 2016. Ongoing

Country/Organization

IRAN

Type

Thesis

Year

2020

Description

Abdulrahman AlOmar (MSc), Synthesis and Preclinical Evaluation of 64Cu-NOTA-Folate: Potential PET radiopharmaceutical for Ovarian Cancer

Country/Organization

SAUDI ARABIA

Type

Abstracts from the Proceedings of a Meeting

Year

2017,

Description

M.A. Avila-Rodriguez, C. Rios, J. Carrasco-Hernandez, J.C. Manrique-Arias, R. Martinez-Hernandez, F.O. Garci´a-Pe´rez, E. Martinez-Rodriguez, M.E. Romero- Pin~a, A.R. Jalilian , A. Diaz-Ruiz, PET-based biodistribution and radiation dosimetry of [64Cu]copper dichloride, first-in- human healthy volunteer evaluation (Oral presentation), EANM 2017 Congress, Vienna, Austria. (Abstract published in EJNMMI 44:S359).

Country/Organization

MEXICO

Type

Thesis

Year

2019

Description

S. Ait-Mohand, PhD, Research professional

Country/Organization

CANADA

Type

Journal

Year

2019

Description

M.A. A´vila-Rodri´guez, E. Aguilar-Orti´z, A.R. Jalilian , J.C. Manrique-Aias, A. Zarate-Morales, A. Flores-Moreno, A simple and efficient method to recover Nickel-64 from electrolytic solutions, Appl. Radiat. Isot. 145, 55-58 (2019).

Country/Organization

Mexico

Type

Thesis

Year

2018

Description

Mário Gutfilen Grünbaum - Development of new radiopharmaceuticals with Cu-64: translational studies. Undergraduate student.

Country/Organization

BRAZIL

Type

Journal

Year

2016

Description

Rubel Chakravarty, Sudipta Chakraborty, Raghumani Singh Ningthoujam, K. V. Vimalnath Nair, K. Shitaljit Sharma, Anand Ballal, Apurav Guleria, Amit Kunwar, Haladhar Dev Sarma, Rajesh Kumar Vatsa, Ashutosh Dash, Industrial-Scale Synthesis of Intrinsically Radiolabeled 64CuS Nanoparticles for Use in Positron Emission Tomography (PET) Imaging of Cancer. Ind. Eng. Chem. Res. 2016; 55, 48: 12407-12419.

Country/Organization

India

Type

Peer-reviewed Journal Article

Year

2017

Description

Davies, G.; Rolle, A.-M.; Maurer, A.; Spycher, P. R.; Schillinger, C.; Solouk-Saran, D.; Hasenberg, M.; Weski, J.; Fonslet, J.; Dubois, A.; et al. Towards Translational ImmunoPET/MR Imaging of Invasive Pulmonary Aspergillosis: The Humanised Monoclonal Antibody JF5 Detects Aspergillus Lung Infections In-vivo. Theranostics 2017, 7 (14), 3398–3414.

Country/Organization

DENMARK

Type

conference

Year

2015

Description

Dale Bailey et al. A Novel Theranostic Trial Design Using 64Cu/67Cu with Fully 3D Pre-Treatment Dosimetry. J Nucl Med, 2019, 60:S1 204.

Country/Organization

Australia

Type

Journal

Year

2016

Description

Petersen, A.L.; Henriksen, J.R.; Binderup, T.; Elema, D.R.; Rasmussen, P.H.; Hag, A.M.; Kjær, A.; Andresen, T.L. In vivo evaluation of PEGylated 64Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT. European Journal of Nuclear Medicine and Molecular Imaging 2016, 43, 941–52.

Country/Organization

Denmark

Type

Journal

Year

2018

Description

eppesen, T.E. Site-Specific Cu-64 Labeling of the Serine Protease, Active Site Inhibited Factor Seven Azide (FVIIai-N-3), Using Copper Free Click Chemistry. BIOCONJUGATE CHEMISTRY 2018, 29, 117–125

Country/Organization

Denmark

Type

Journal

Year

2019

Description

Kristensen, L.K. PET imaging of tumor-immune status for response prediction and treatment monitoring in syngeneic mouse models. Cancer Research 2019, 79, 1130

Country/Organization

Denmark

Type

Thesis

Year

2019

Description

Jhonatan Carrasco-Hernandez (Doctorate), Evaluating the potential of [64Cu]CuCl2 as a theranostic agent.

Country/Organization

MEXICO

Type

Journal

Year

2018

Description

E. Aguilar-Orti´z, A.R. Jalilian, M.A. Avila-Rodriguez, Porphyrins as Ligands for 64Copper: Background and Trends, Med. Chem. Comm. 9, 1577-88 (2018).

Country/Organization

Mexico

Type

Abstracts from the Proceedings of a Meeting

Year

2017

Description

"Preparation and preclinical evaluation of 64Cu-NOTA-anti MUC1 as a radioimmunoconjugate for diagnosis of MUC1 breast cancer by PET" (EANM 17)- 2017-Vienna-Austria

Country/Organization

IRAN

Type

Ph.D Dissertation/Master’s Theses

Year

2016

Description

Ms.c Thesis: Preparation and preclinical evaluation of 64Cu-NOTA- Anti MUC1 for PET Imaging of MUC1+ breast adeno Carcinoma. Started From 2017. Ongoing.

Country/Organization

IRAN

Type

Thesis

Year

2019

Description

M. Paquette, PhD, Post-Doc

Country/Organization

CANADA

Type

Post doctoral Research Protocol:

Year

2017-NOW

Description

Edgar A. Aguilar-Ortiz, Synthesis, characterization and evaluation of macrocyclic porphyrin systems, as potential chelate agents for 64Cu-radiopharmaceuticals.

Country/Organization

MEXICO

Type

Thesis

Year

2019

Description

Carlos A. Gomez-Peralta (Master), Quantitative analysis of the brain biodistribution of [64Cu]CuCl2 in patients with Parkinson’s disease.

Country/Organization

MEXICO

Type

Conference

Year

2019

Description

Kristensen, L.K. PET imaging of tumor-immune status for response prediction and treatment monitoring in syngeneic mouse models. Cancer Research 2019, 79, 1130.

Country/Organization

Denmark

Type

conference

Year

2019

Description

B. Guérin, Optimizing care for prostate cancer patients using molecular imaging and targeted radioligand therapy. 11th Scientific Day QBIN, Montreal, Quebec, CA, March 29th, 2019.

Country/Organization

Canada

Type

Journal

Year

2018

Description

Jensen, A.I.; Severin, G.W.; Hansen, A.E.; Fliedner, F.P.; Eliasen, R.; Parhamifar, L.; Kjaer, A.; Andresen, T.L.; Henriksen, J.R. Remote-loading of liposomes with manganese-52 and in vivo evaluation of the stabilities of Mn-52-DOTA and Cu-64-DOTA using radiolabelled liposomes and PET imaging. J. Control. Release 2018, 269, 100–109

Country/Organization

Denmark

Type

Conference

Year

2017

Description

M.A. Avila-Rodriguez, C. Rios, J. Carrasco-Hernandez, J.C. Manrique-Arias, R. Martinez-Hernandez, F.O. Garci´a-Pe´rez, E. Martinez-Rodriguez, M.E. Romero- Pin~a, A.R. Jalilian , A. Diaz-Ruiz, PET-based biodistribution and radiation dosimetry of [64Cu]copper dichloride, first-in-human healthy voluteer evaluation, EJNMMI 44, S359 (2017).

Country/Organization

Mexico

Type

Journal

Year

2016

Description

Frellsen, A.F.; Hansen, A.E.; Jolck, R.I.; Kempen, P.J.; Severin, G.W.; Rasmussen, P.H.; Kjaer, A.; Jensen, A.T.I.; Andresen, T.L. Mouse Positron Emission Tomography Study of the Biodistribution of Gold Nanoparticles with Different Surface Coatings Using Embedded Copper-64. ACS Nano 2016, 10, 9887–9898.

Country/Organization

Denmark

Type

Journal

Year

2017

Description

Christensen, A.; Juhl, K.; Persson, M.; Charabi, B.W.; Mortensen, J.; Kiss, K.; Lelkaitis, G.; Rubek, N.; von Buchwald, C.; Kjær, A. uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: Proof-of-concept in orthotopic xenograft model. Oncotarget 2017, 8, 15407–15419

Country/Organization

Denmark

Type

Conference

Year

2019

Description

M.A. Avila-Rodriguez, Preparation and quality control of ready for injection [64Cu]copper dichloride solution for theranostic applications, J. Label. Compd. Radiopharm. 62, S258 (2019).

Country/Organization

Mexico

Type

conference

Year

2019

Description

Thaer Assaad, Abdul. Hamid Al Rayyes, and Mahmoud. Al-Ktaifani , In house preparation and biodistribution of 64Cu-ATSM, 64Cu-PTSM and 64Cu-DOTATATE for theranostic application. ISTR 2019, IAEA .

Country/Organization

Syria

Type

conference

Year

2019

Description

Authors: Irfan Ullah Khan, Rizwana Zahoor, Abubaker Shahid, Fozia Iram, Capacity Building in Theranostics: Initial Experience at INMOL-Lahore being First Theranostics Centre in Pakistan, Theranostics World Congress 2019; held in Jeju, Korea

Country/Organization

Pakistan

Type

conference

Year

2017

Description

M. Paquette, S. Ait-Mohand, V. Dumulon-Perreault, F. Bénard, B. Guérin. A Novel 64Cu/NOTA-labeled Peptide with High Metabolic-resistance and NPY-Y1R Affinity. 100th Canadian Chemistry Conference and Exhibition. Symposium in the Biological and Medicinal Chemistry Division, Metro Toronto Convention Centre. Canada May 30, 2017.

Country/Organization

Canada

Type

Journal

Year

2018

Description

hristensen, E.; Henriksen, J.R.; Jørgensen, J.T.; Amitay, Y.; Schmeeda, H.; Gabizon, A.A.; Kjær, A.; Andresen, T.L.; Hansen, A.E. Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts. International Journal of Nanomedicine 2018, 13, 7647–7656.

Country/Organization

Denmark

Type

Conference

Year

2016

Description

N. Mansour, M. Paquette, S. Ait-Mohand, V. Dumulon-Perreault, R. Lecomte, B. Guérin. A Novel Radiolabeled Peptide for PET Imaging of Prostate Cancer: 64Cu-DOTHA2-PEG-RM26: ESRR’16 – 18th European Symposium on Radiopharmacy and Radiopharmaceuticals, April 07-10, 2016, Salzburg, Austria. EJNMMI Radiopharm. Chem. 2016, S1 OP27.

Country/Organization

Canada

Type

Journal

Year

2016

Description

Behrouz Alirezapour, Mohammad Javad Rasaee, Amir Reza Jalilian, Saeed Rajabifar, Javad Mohammadnejad, Malihe Paknejad,Ehsan Maadi, Sedighe Moradkhani.” Development of 64Cu-DOTA-PR81 radioimmunoconjugate for MUC-1 positive PET imaging”. Nuclear Medicine and Biology. Vol. 43, No. 1, 2016

Country/Organization

Iran

Type

Ph.D Dissertation/Master’s Theses

Year

2017

Description

Carlos A. Gomez-Peralta (Master’s degree), Quantitative analysis of the brain biodistribution of [64Cu]CuCl2 in patients with Parkinson’s disease.

Country/Organization

MEXICO

Type

review

Year

2020

Description

IAEA contribution to the development of copper-64 radiopharmaceuticals for theranostic applications, Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna International Centre, PO Box 100, 1400, Vienna, Austria, 20 Contributers

Country/Organization

IAEA

Type

Journal

Year

2018

Description

Hansen, A.E.; Fliedner, F.P.; Henriksen, J.R.; Jørgensen, J.T.; Clemmensen, A.E.; Børresen, B.; Elema, D.R.; Kjær, A.; Andresen, T.L. Liposome accumulation in irradiated tumors display important tumor and dose dependent differences. Nanomedicine: Nanotechnology, Biology and Medicine 2018, 14, 27–34.

Country/Organization

Denmark

Type

Conference

Year

2019

Description

E. Aguilar-Ortiz, A. Jalilian, M. Ávila-Rodríguez, Synthesis, characterization and labeling of [64Cu]-5-(4aminophenyl)-10,15,20-triphenyl porphyrine as a potential PET imaging chelate, Nucl. Med. Biol. 72–73 (2019) 36.

Country/Organization

Mexico

Type

Journal

Year

2017

Description

Rubel Chakravarty, Sudipta Chakraborty, Apurav Guleria, Amit Kunwar, Haladhar Dev Sarma, Ashutosh Dash. Facile One-Pot Synthesis of Intrinsically Radiolabeled 64Cu-Human Serum Albumin Nanocomposite for Cancer Targeting. ChemistrySelect 2017; 2 (26): 8043-8051.

Country/Organization

India

Type

Journal

Year

2016

Description

J.C. Manrique-Arias, J. Carrasco-Herna´ndez, P.G. Reyes, M.A. Avila-Rodriguez, Biodistribution in rats and human dosimetry estimation of 64CuCl2, a potential theranostic tracer, Appl. Radiat. Isot. 115, 18-22 (2016).

Country/Organization

Mexico

Type

Ph.D Dissertation/Master’s Theses

Year

2016

Description

PhD Thesis: Preparation and Biological in vitro and in vivo evaluation of 64Cu-NOTA-Anti ROR1 for diagnosis and follow up of ROR1+ breast carcinoma.

Country/Organization

IRAN

Type

Conference

Year

2017

Description

C. Zhang, J. Pan, K.-S. Lin, J. Zeisler, B. Guerin, and F. Benard. Stabilizing truncated peptides targeting the neuropeptide Y1 receptor for cancer imaging. J Nucl Med 2017 58:693. Society of Nuclear Medicine Annual Meeting, SNMMI 2017, Denver, Colorado, USA, June 10-14, 2017. JNM 2017

Country/Organization

Canada

Type

Thesis

Year

2019

Description

V. Dumulon Perreault, M. Sc., Research assistant

Country/Organization

CANADA

Type

Thesis

Year

2019

Description

Armando S. Ordoñez-Canul (Master), Copper-64 radiolabeled trastuzumab for PET molecular imaging of HER2+ tumors.

Country/Organization

MEXICO

Type

Journal

Year

2017

Description

Jensen, A.T.I. PET imaging with copper-64 as a tool for real-time in vivo investigations of the necessity for crosslinking of polymeric micelles in nanomedicine. Journal of Labelled Compounds and Radiopharmaceuticals 2017, 60, 366–374

Country/Organization

Denmark

Type

conference

Year

2019

Description

Preparation and Preclinical Evaluation of 64Cu-NOTA-anti MUC1 as a Radioimmunoconjugate for Diagnosis of MUC1+ breast cancer by PET, 2nd International Symposium of Trends of Radiopharmaceuticals (IAEA), Location: Viena, Austria, 2019

Country/Organization

Iran

Type

Journal

Year

2019

Description

Rodney John Hicks, Price Jackson, Grace Kong, et al. First-in-human trial of 64Cu-SARTATE PET imaging of patients with neuroendocrine tumours demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. J Nucl Med. 2019 Jun;60(6):777-785

Country/Organization

Australia

Type

conference

Year

2018

Description

B. Guérin, Tools for peptide radiolabeling, Clara Benson Award Lecture, Sponsored by the Canadian Council of University Chemistry Chairs (CCUCC).101st Canadian Chemistry Conference and Exhibition, May 27-31, 2018; Edmonton, AB, Canada.

Country/Organization

Canada

Type

Peer-reviewed Journal Article

Year

2017

Description

Avila-Rodriguez, M.A., Rios, C., Carrasco-Hernandez, J., Manrique-Arias, J.C., Martinez-Hernandez, F.O. Garci´a-Pe´rez, A.R. Jalilian, E. Martinez-Rodriguez, M.E. Romero-Pin~a, A. Diaz-Ruiz, Biodistribution and Radiation Dosimetry of [64Cu]Copper Dichloride: First-in-Human Study in Healthy Volunteers, Eur J Nucl Med Mol Imaging Research. 7, 98

Country/Organization

MEXICO

Type

Ph.D Dissertation/Master’s Theses

Year

2018

Description

Romano Silviano Bonito Hendriko Schreuder, Development of 64Cu-labeled radiopharmaceuticals for neuroendocrine tumor detection with positron emission tomography: A comparison between 64Cu-NODAGA-NOC, 68Ga-NODAGA-NOC and 68Ga-DOTA-TOC

Country/Organization

THE NETHERLANDS

Type

Journal

Year

2016

Description

Rubel Chakravarty, Sudipta Chakraborty, Ashutosh Dash 64Cu2+ Ions as PET Probe: An Emerging Paradigm in Molecular Imaging of Cancer. Mol Pharm. 2016; 13(11): 3601-3612.

Country/Organization

India

Stay in touch

Newsletter